Ipsen Biopharmaceuticals, Inc.
1 Main Street
Unit 700
Cambridge
MA
02142
United States
Tel: 617-679-8500
Website: https://www.ipsenus.com/
Email: talentacquisition@ipsen.com
About Ipsen Biopharmaceuticals, Inc.
Ipsen (Euronext: IPN; ADR: IPSEY) is a global, biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases. At Ipsen, we focus our resources, investments and energy on discovering, developing and commercializing new therapeutic options to provide hope for patients whose lives are challenged by difficult-to-treat diseases. Ipsen's North American operations and headquarters are located in Cambridge, Massachusetts, where our fully integrated biopharmaceutical team across External Innovation and Partnering, Research & Development (R&D), Manufacturing and Commercial collaborate. Cambridge is home to Ipsen's third global hub, in addition to R&D centers in Paris-Saclay in France and Oxford in the United Kingdom. With additional offices in Basking Ridge, N.J. and Mississauga, Ontario, Ipsen employs approximately 600 people in North America. For more information on Ipsen in North America, please visit www.ipsenus.com or www.ipsen.ca.
597 articles about Ipsen Biopharmaceuticals, Inc.
-
Ipsen: Total Number of Outstanding Shares and Voting Rights, Pursuant to Article 223-16 of the General Regulation of the Autorité des Marchés Financiers
7/8/2008
-
Half-Year Statement of Ipsen's Liquidity Contract
7/3/2008
-
Ipsen Completes Purchase of Apokyn®, Vernalis PLC's US Commercial Operations and Share Subscription
7/1/2008
-
Ipsen: Roche Moves Investigational Diabetes Drug, Taspoglutide, into Phase III Clinical Trials
6/10/2008
-
Ipsen: Total Number of Outstanding Shares and Voting Rights, Pursuant to Article 223-16 of the General Regulation of the Autorité Des Marchés Financiers
6/6/2008
-
Ipsen In 3 Deals Worth $450M; Company to Build A Fully-Fledged Commercial Presence In North America -- $404M Tercica, Inc. Merger Deal; Vernalis PLC To Sell Apokyn And U.S. Commercial Operations for $17.5M; Octagon Corp. to be Acquired
6/5/2008
-
Ipsen's Annual Shareholders’ Meeting on 4 June 2008
6/4/2008
-
Ipsen and Spirogen's SJG-136 Shows Encouraging Results in the Treatment of Refractory Solid Tumours At American Society of Clinical Oncology
6/2/2008
-
Ipsen: Appointment of Gérard Picot as Vice President, Global Regulatory Affairs
5/22/2008
-
Ipsen and Medicis Announce Acceptance of Reloxin(R) BLA in Aesthetics by FDA
5/19/2008
-
Ipsen: Total Number of Outstanding Shares and Voting Rights, Pursuant to Article 223-16 of the General Regulation of the Autorité Des Marchés Financiers
5/14/2008
-
Ipsen: Adenuric(R) (Febuxostat) Receives Marketing Authorisation in the European Union
5/5/2008
-
Ipsen's First Quarter 2008 Sales
4/29/2008
-
Ipsen: Appointment of Dominique Bridon, PhD as Vice President, Discovery
4/1/2008
-
Ipsen: Appointment of Frédéric Babin as Executive Vice President, Human Resources
3/18/2008
-
Ipsen and Medicis Announce Submission of Reloxin(R) BLA in Aesthetics to the FDA
3/17/2008
-
Ipsen: Total Number of Outstanding Shares and Voting Rights, Pursuant to Article 223-16 of the General Regulation of The Autorité des Marchés Financiers
3/7/2008
-
Ipsen's Full Year 2007 Results and Financial Objectives for the Full Year 2008
2/27/2008
-
Ipsen: Total Number of Outstanding Shares and Voting Rights, Pursuant to Article 223-16 of the General Regulation of the Autorité Des Marchés Financiers
2/15/2008
-
Ipsen: Clinical Update For Decapeptyl(R) 6-Month Formulation in Advanced Prostate Cancer
2/12/2008